Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : UpScriptHealth
Deal Size : Undisclosed
Deal Type : Collaboration
Tolmar, UpScriptHealth Boost Access to Oral Testosterone Therapy
Details : UpScriptHealth will provide telehealth consultations for Jatenzo (testosterone undecanoate), an oral TRT for adult men who have low or no testosterone, including hypogonadism.
Product Name : Jatenzo
Product Type : Hormone
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : UpScriptHealth
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rucaparib Camsylate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : pharma&
Deal Size : Undisclosed
Deal Type : Agreement
pharma& Group Promotes Rubraca® For Metastatic Prostate Cancer in U.S.
Details : Under the terms of the Agreement, Tolmar will be responsible for U.S. marketing and sales activities to promote Rubraca (rucaparib) for BRCA-mutated Ovarian Cancer.
Product Name : Rubraca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : Rucaparib Camsylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : pharma&
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
Details : Undisclosed
Product Name : Jatenzo
Product Type : Hormone
Upfront Cash : Inapplicable
April 26, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Clarus Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Following a competitive auction process, Tolmar was selected as the winning bidder in the sale of JATENZO (testosterone undecanoate), and the sale was approved by the U.S. Bankruptcy Court for the District of Delaware.
Product Name : Jatenzo
Product Type : Hormone
Upfront Cash : Undisclosed
October 27, 2022
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Clarus Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Ottawa Hospital Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 23, 2021
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Ottawa Hospital Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company's lead product, ELIGARD®, is a luteinizing hormone releasing hormone (LHRH) agonist indicated for the treatment of advanced prostate cancer.
Product Name : Eligard
Product Type : Peptide
Upfront Cash : Inapplicable
December 04, 2021
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under terms of the agreement, Tolmar’s sales force will promote ALKINDI SPRINKLE® to their pediatric endocrinology targets alongside FENSOLVI®. ALKINDI SPRINKLE® (hydrocortisone) oral granules is FDA-approved as replacement therapy for Adrenocortica...
Product Name : Alkindi Sprinkle
Product Type : Steroid
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD in Canada
Details : Throughout the transition, Sanofi Canada and Tolmar are collaborating fully to help ensure smooth transfer of the product and services for patients and healthcare providers, including the ELIGARD® Home Injection Program in place in Canada.
Product Name : Eligard
Product Type : Peptide
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 28, 2021